Invention of novel cancer drug for refractory solid tumor

2015 Fiscal Year Final Research Report

• Project/Area Number: 25430165
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Kanagawa Cancer Center Research Institute
• Principal Investigator: YAMADA ROPPEI 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター(臨床研究所), その他部局等, その他 (30404974)
• Co-Investigator(Kenkyū-buntansha): Miyagi Yohei 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター臨床研究所, がん分子病態学部 (00254194)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 難治性固形腫瘍 / 活性酸素

Outline of Final Research Achievements

We discontinued the invention of PACMA31 as a PDI inhibitor, because our data did not show reproduction. But PACMA5, other PACMA derivative, had four novel findings. 1) It showed potency for not normal cells but cancer cells. 2) It induced non-apoptotic cell death via ROS generation. 3) It showed efficacy for ovarian peritoneal dissemination. 4)Its target protein is Protein 1 (tentative name) which is closely related to ROS generation. Thus we believed PACMA5 can be a new candidate of a novel cancer drug for refractory solid tumor.

Free Research Field

腫瘍治療学